KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Other Non Operating Income (2016 - 2026)

AbbVie has reported Other Non Operating Income over the past 14 years, most recently at -$5.7 billion for Q4 2025.

  • Quarterly Other Non Operating Income fell 30142.11% to -$5.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.8 billion through Dec 2025, down 1532.84% year-over-year, with the annual reading at -$5.8 billion for FY2025, 27485.71% down from the prior year.
  • Other Non Operating Income was -$5.7 billion for Q4 2025 at AbbVie, down from -$20.0 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $3.0 billion in Q4 2023 and troughed at -$5.7 billion in Q4 2025.
  • The 5-year median for Other Non Operating Income is -$19.5 million (2024), against an average of -$474.0 million.
  • Year-over-year, Other Non Operating Income surged 8722.22% in 2022 and then plummeted 263800.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $2.2 billion in 2021, then plummeted by 190.51% to -$2.0 billion in 2022, then surged by 247.2% to $3.0 billion in 2023, then plummeted by 100.64% to -$19.0 million in 2024, then tumbled by 30142.11% to -$5.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Other Non Operating Income are -$5.7 billion (Q4 2025), -$20.0 million (Q3 2025), and -$2.6 billion (Q2 2025).